NDP — Norrin F-box protein

The NDP gene provides the instructions for making a protein called norrin. Norrin acts like a chemical messenger in the body, specifically helping to guide the growth and development of blood vessels. It is especially important in the eyes and the inner ears. In the eye, norrin tells the cells how to form the complex network of blood vessels needed to supply oxygen and nutrients to the retina, which is the light-sensitive tissue at the back of the eye. It also helps maintain the blood vessels in the inner ear, which are necessary for normal hearing. When there is a mutation (a harmful change) in the NDP gene, the norrin protein either doesn't work correctly or isn't produced at all. Without functional norrin, the blood vessels in the retina do not develop properly. The retina becomes starved of oxygen, which causes the eye to grow abnormal, leaky blood vessels and scar tissue. This can lead to the retina detaching from the back of the eye, causing severe vision loss or complete blindness. Because norrin is also needed in the ear, some people with these mutations may also develop hearing loss as they get older. Diseases caused by NDP mutations are inherited in an X-linked recessive pattern. This means the gene is located on the X chromosome. Because males have only one X chromosome, a single mutated copy of the gene is enough to cause the disease. Females have two X chromosomes, so if they inherit one mutated copy, the normal copy usually compensates, making them "carriers" who typically do not show severe symptoms. The most severe condition caused by this gene is called Norrie disease, which causes blindness at birth. Milder mutations can cause conditions like familial exudative vitreoretinopathy (FEVR) or Coats disease, which also affect the eye's blood vessels but may not cause total blindness.

Gene description: The NDP gene encodes norrin, a secreted growth factor that is critical for retinal vascular development and neurogenesis.

Patient and family guide: The NDP gene provides the instructions for making a protein called norrin. Norrin acts like a chemical messenger in the body, specifically helping to guide the growth and development of blood vessels. It is especially important in the eyes and the inner ears. In the eye, norrin tells the cells how to form the complex network of blood vessels needed to supply oxygen and nutrients to the retina, which is the light-sensitive tissue at the back of the eye. It also helps maintain the blood vessels in the inner ear, which are necessary for normal hearing. When there is a mutation (a harmful change) in the NDP gene, the norrin protein either doesn't work correctly or isn't produced at all. Without functional norrin, the blood vessels in the retina do not develop properly. The retina becomes starved of oxygen, which causes the eye to grow abnormal, leaky blood vessels and scar tissue. This can lead to the retina detaching from the back of the eye, causing severe vision loss or complete blindness. Because norrin is also needed in the ear, some people with these mutations may also develop hearing loss as they get older. Diseases caused by NDP mutations are inherited in an X-linked recessive pattern. This means the gene is located on the X chromosome. Because males have only one X chromosome, a single mutated copy of the gene is enough to cause the disease. Females have two X chromosomes, so if they inherit one mutated copy, the normal copy usually compensates, making them "carriers" who typically do not show severe symptoms. The most severe condition caused by this gene is called Norrie disease, which causes blindness at birth. Milder mutations can cause conditions like familial exudative vitreoretinopathy (FEVR) or Coats disease, which also affect the eye's blood vessels but may not cause total blindness.

Gene function: Norrin, encoded by NDP, is a ligand for the Frizzled-4 receptor, activating the Wnt signaling pathway. This pathway is vital for the proper formation of the retinal vasculature during development, ensuring adequate blood supply to the retina. It also plays a role in maintaining retinal neuronal health and integrity.

Protein structure: The NDP gene encodes a 133-amino acid precursor protein that includes a 24-amino acid N-terminal signal peptide, which is cleaved to produce the mature 109-amino acid secreted norrin protein. The defining structural feature of norrin is its cystine-knot motif, located in the C-terminal region. This domain contains highly conserved cysteine residues that form a rigid structure of intramolecular disulfide bonds, characteristic of the cystine-knot growth factor family (which includes proteins like TGF-β and PDGF). Norrin functions as a homodimer, meaning two norrin molecules bind together to form the active protein complex. The dimerization is stabilized by three intermolecular disulfide bonds. This dimeric structure is essential for its biological activity, as it allows the complex to simultaneously bind to the Frizzled-4 (FZD4) receptor and the LRP5/6 coreceptor, effectively bridging them to initiate intracellular signaling. Mutations that disrupt the cysteine residues or the dimerization interface severely impair the protein's ability to fold correctly and activate its target receptors.

Molecular function: The NDP gene encodes norrin, a secreted signaling protein that functions as a high-affinity ligand for the canonical Wnt/β-catenin signaling pathway. Despite lacking sequence homology to traditional Wnt proteins, norrin specifically binds to the Frizzled-4 (FZD4) receptor and the coreceptors LRP5 (or LRP6) and TSPAN12 on the surface of vascular endothelial cells. This binding complex initiates a signaling cascade that inhibits the degradation of β-catenin, allowing it to accumulate in the cytoplasm and translocate to the nucleus. Once in the nucleus, β-catenin interacts with TCF/LEF transcription factors to drive the expression of target genes essential for angiogenesis and the formation of the blood-retinal barrier (BRB). In the retina, norrin is secreted by Müller glia and acts in a paracrine manner on endothelial tip cells to guide the radial extension and deep penetration of retinal capillaries. This signaling is absolutely required for the development of the intermediate and deep capillary plexuses of the retina and for maintaining the tight junctions that prevent vascular leakage. In the absence of functional norrin, the retinal vasculature fails to develop fully, leading to severe tissue hypoxia. This hypoxic state triggers the upregulation of vascular endothelial growth factor (VEGF), which promotes aberrant, leaky neovascularization. The resulting imbalance between defective Wnt signaling and excessive VEGF signaling drives the pathogenesis of NDP-related retinopathies, characterized by fibrovascular proliferation, exudation, and retinal detachment.

Expression pattern: The NDP gene is primarily expressed in the neuroretina, specifically by Müller glia cells, during embryonic development and postnatal life. It is secreted into the extracellular space where it acts on adjacent vascular endothelial cells. This localized expression is critical for the development and maintenance of the intraretinal capillary networks. Expression is upregulated by hypoxia, which serves as a physiological trigger to promote angiogenesis during retinal development. Beyond the eye, NDP is also expressed in the inner ear, where it is essential for the vascularization and maintenance of the stria vascularis, a structure vital for hearing. Additionally, norrin expression has been detected in the brain, olfactory bulb, and reproductive organs, which correlates with the systemic features (such as intellectual disability and seizures) seen in severe cases of Norrie disease. The widespread but specific tissue expression pattern underscores norrin's role in coordinating vascular development in specialized sensory and neurological tissues.

Mutation spectrum: Over 200 pathogenic variants have been identified in the NDP gene, encompassing a wide spectrum of mutation types. These include missense mutations, nonsense mutations, frameshifts (insertions and deletions), splice-site alterations, and large genomic deletions that can encompass the entire gene or extend into neighboring genes. The majority of these mutations are clustered within the third exon, which encodes the highly conserved cystine-knot domain critical for the protein's structural integrity and receptor binding capabilities. Mutations that alter the highly conserved cysteine residues within the cystine-knot motif are particularly common and invariably lead to severe protein misfolding and loss of function. While there are no single predominant founder mutations globally, certain variants have been reported recurrently in specific populations. The type of mutation strongly influences the resulting phenotype, with truncating mutations and large deletions generally causing severe Norrie disease, while missense mutations outside the core structural domains often result in milder exudative vitreoretinopathies.

Pathogenic variants: 1. p.Arg121Trp (c.361C>T) - A well-characterized missense mutation frequently associated with X-linked familial exudative vitreoretinopathy (FEVR). It impairs norrin's ability to activate the Wnt signaling pathway while maintaining some residual function, leading to a milder phenotype. 2. p.Cys95Phe (c.284G>T) - A missense mutation that disrupts a critical cysteine residue within the cystine-knot domain. This prevents proper disulfide bond formation and protein folding, resulting in classic, severe Norrie disease. 3. p.Arg37Ter (c.109C>T) - A nonsense mutation that introduces a premature stop codon early in the protein sequence. This leads to a truncated, non-functional protein or nonsense-mediated decay, causing severe Norrie disease with congenital blindness and systemic features. 4. p.His42Arg (c.125A>G) - A missense mutation that has been reported in patients with varying phenotypes, including Norrie disease and severe FEVR, highlighting the variable expressivity of certain NDP variants. 5. c.22_25dupGCAT - A frameshift mutation caused by a small duplication, leading to a premature stop codon and complete loss of functional norrin. This variant is associated with classic Norrie disease, including auditory impairments.

Clinical significance: Mutations in the NDP gene cause a spectrum of X-linked recessive conditions collectively known as NDP-related retinopathies. The most severe manifestation is Norrie disease, which is characterized by bilateral congenital blindness due to dense fibrovascular masses (pseudogliomas) behind the lens, retinal detachment, and atrophy of the globe (phthisis bulbi). Beyond the ocular findings, approximately 30-50% of males with Norrie disease develop progressive sensorineural hearing loss, typically beginning in the second or third decade of life, and up to 30% may experience intellectual disability, developmental delays, or seizures. Milder phenotypes associated with NDP mutations include X-linked familial exudative vitreoretinopathy (FEVR), Coats disease, and persistent hyperplastic primary vitreous (PHPV). FEVR is characterized by incomplete vascularization of the peripheral retina, leading to retinal ischemia, neovascularization, and varying degrees of vision loss, which can range from asymptomatic peripheral non-perfusion to severe exudative or tractional retinal detachment. Coats disease involves abnormal, leaky retinal blood vessels that cause massive subretinal exudation and cholesterol deposition. The severity of these conditions is highly variable, even among individuals with the same mutation, though the clinical presentation is generally less severe than classic Norrie disease and typically lacks the systemic neurological and auditory features.

Inheritance: X-linked Recessive

Chromosomal location: Xp11.4

Genotype-phenotype correlations: There is a well-established genotype-phenotype correlation in NDP-related retinopathies. Severe mutations, such as large deletions, nonsense mutations, and frameshifts that result in a complete loss of norrin protein function or early truncation, are almost exclusively associated with classic Norrie disease. These patients present with congenital blindness, and a high proportion develop sensorineural hearing loss and intellectual disability. Mutations that disrupt the critical cystine-knot domain, preventing proper folding or dimerization of the protein, also typically result in the severe Norrie disease phenotype. Conversely, missense mutations that cause partial loss of function or affect less critical regions of the protein are more commonly associated with milder phenotypes, such as X-linked familial exudative vitreoretinopathy (FEVR) or Coats disease. In these cases, sufficient norrin activity remains to support partial retinal vascularization, sparing the patient from congenital blindness and systemic manifestations. However, clinical expressivity can still vary significantly among individuals with the same missense mutation, suggesting that other genetic modifiers or environmental factors may influence the final clinical outcome.

Research and therapeutic approaches: Currently, there are no FDA-approved pharmacological or gene therapies specifically for NDP-related retinopathies. Standard of care relies on surgical and medical management of the complications. This includes prophylactic laser photocoagulation or cryotherapy to the avascular peripheral retina to prevent neovascularization and exudation in milder cases like FEVR or Coats disease. In more advanced cases with retinal detachment, vitreoretinal surgery (vitrectomy and scleral buckling) is performed, though outcomes in severe Norrie disease are often poor. Anti-VEGF injections (such as bevacizumab) are increasingly used off-label to reduce exudation and neovascularization, addressing the secondary effects of the disease. However, significant progress is being made in preclinical pipeline therapies, particularly gene therapy. Researchers are utilizing adeno-associated virus (AAV) vectors to deliver functional copies of the NDP gene in animal models. Recent studies in Ndp knockout mice have demonstrated that systemic or targeted AAV-mediated gene therapy can successfully rescue retinal vascularization, restore the blood-retinal barrier, and significantly reduce progressive sensorineural hearing loss. These promising preclinical results are paving the way for future human clinical trials, aiming to provide a definitive treatment that addresses the root genetic cause of Norrie disease and related retinopathies.

Diagnostic testing: Diagnosis of NDP-related retinopathies relies on a combination of clinical evaluation, specialized ophthalmic imaging (such as fluorescein angiography to detect peripheral avascularity and neovascularization), and molecular genetic testing. Genetic testing typically involves targeted gene panels for inherited retinal diseases or whole exome sequencing (WES) to identify pathogenic variants in the NDP gene. In cases where a specific familial mutation is known, targeted single-gene testing can be performed. Genetic counseling is a critical component of the diagnostic process, given the X-linked recessive inheritance pattern. Female carriers are usually asymptomatic but have a 50% chance of passing the mutated gene to their offspring; male offspring who inherit the mutation will be affected, while female offspring will be carriers. However, some female carriers may exhibit mild retinal vascular anomalies. Preimplantation genetic diagnosis and prenatal testing are available for families with a known pathogenic NDP variant. Early diagnosis in affected males is crucial for prompt intervention, such as laser photocoagulation or surgery, to preserve any remaining vision and to monitor for the onset of hearing loss and developmental issues.

Animal models: The primary animal model used to study NDP-related retinopathies is the Ndp knockout mouse (Ndptm1Wbrg or Ndph-knockout). This model closely recapitulates the human ocular phenotype, exhibiting abnormal retinal vascularization, failure of the deep capillary networks to form, and subsequent hypoxia-induced neovascularization. The lack of norrin in these mice leads to a porous blood-retinal barrier, resulting in subretinal exudation and an electronegative electroretinogram (ERG), mirroring the clinical features of Norrie disease and familial exudative vitreoretinopathy (FEVR). Additionally, these mouse models have been instrumental in studying the extraocular manifestations of Norrie disease, particularly progressive sensorineural hearing loss. Research utilizing Ndp knockout mice has demonstrated that norrin is essential for the maintenance of the stria vascularis and hair cells in the inner ear. These models are currently being used extensively in preclinical trials to evaluate the efficacy of systemic and targeted gene therapies aimed at rescuing both retinal dysfunction and hearing loss.

Population genetics: NDP-related retinopathies are extremely rare, and precise global prevalence data is limited. Norrie disease and X-linked FEVR affect males almost exclusively due to the X-linked recessive inheritance pattern. The carrier frequency in the general population is very low, and there are no major population-specific founder effects that significantly elevate the prevalence in specific ethnic groups, though isolated families with recurrent mutations have been documented. Because the conditions are rare and often severe, many cases arise from de novo (new) mutations in the affected individual or the carrier mother, rather than being passed down through many generations. Genetic prevalence estimators suggest that the overall carrier frequency for severe X-linked retinal dystrophies like Norrie disease is a small fraction of a percent globally.

Selected references: 1. Berger W, et al. Isolation of a candidate gene for Norrie disease by positional cloning. Nat Genet. 1992. PMID: 1338905 2. Xu Q, et al. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell. 2004. PMID: 15035989 3. Wawrzynski J, et al. Spectrum of Mutations in NDP Resulting in Ocular Disease. Front Genet. 2022. PMID: 35646068 4. Scruggs BA, et al. NDP-Related Retinopathies. GeneReviews. 2023. PMID: 20301505 5. MacDonald BT, et al. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009. PMID: 19596234 6. Ye X, et al. Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization. Cell. 2009. PMID: 19837032 7. Pauzuolyte V, et al. Systemic gene therapy rescues retinal dysfunction and hearing loss in a model of Norrie disease. EMBO Mol Med. 2023. PMID: 37642150